Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Alzheimer’s disease: the new promise.

Strittmatter WJ.

J Clin Invest. 2012 Apr;122(4):1191. No abstract available.

2.

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.

Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG.

J Clin Invest. 2012 Apr;122(4):1339-53. doi: 10.1172/JCI57256.

3.

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE.

J Clin Invest. 2012 Apr;122(4):1316-38. doi: 10.1172/JCI59903.

4.

The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.

Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, O'Neill C.

Neuromolecular Med. 2013 Mar;15(1):102-14. doi: 10.1007/s12017-012-8199-5. Epub 2012 Sep 21.

PMID:
23011726
5.

Alzheimer's disease and insulin resistance: translating basic science into clinical applications.

De Felice FG.

J Clin Invest. 2013 Feb;123(2):531-9. doi: 10.1172/JCI64595. Epub 2013 Feb 1. Review.

6.

TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys.

Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, Sathler LB, Brito-Moreira J, Amaral OB, Silva CA, Freitas-Correa L, Espírito-Santo S, Campello-Costa P, Houzel JC, Klein WL, Holscher C, Carvalheira JB, Silva AM, Velloso LA, Munoz DP, Ferreira ST, De Felice FG.

Cell Metab. 2013 Dec 3;18(6):831-43. doi: 10.1016/j.cmet.2013.11.002.

7.

Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.

Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, Piantelli M, Di Ilio C, Consoli A, Sensi SL.

Cell Death Dis. 2013 May 2;4:e612. doi: 10.1038/cddis.2013.139.

8.

Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease.

Freude S, Hettich MM, Schumann C, Stöhr O, Koch L, Köhler C, Udelhoven M, Leeser U, Müller M, Kubota N, Kadowaki T, Krone W, Schröder H, Brüning JC, Schubert M.

FASEB J. 2009 Oct;23(10):3315-24. doi: 10.1096/fj.09-132043. Epub 2009 Jun 1.

9.

Alzheimer disease: Insulin resistance and AD--extending the translational path.

Craft S.

Nat Rev Neurol. 2012 Jun 19;8(7):360-2. doi: 10.1038/nrneurol.2012.112. No abstract available.

PMID:
22710630
10.

Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease.

Giuffrida ML, Tomasello F, Caraci F, Chiechio S, Nicoletti F, Copani A.

Mol Neurobiol. 2012 Dec;46(3):605-13. doi: 10.1007/s12035-012-8313-6. Epub 2012 Aug 12. Review.

PMID:
22886436
11.
12.

(-)-Epigallocatechin-3-gallate alleviates spatial memory impairment in APP/PS1 mice by restoring IRS-1 signaling defects in the hippocampus.

Jia N, Han K, Kong JJ, Zhang XM, Sha S, Ren GR, Cao YP.

Mol Cell Biochem. 2013 Aug;380(1-2):211-8. doi: 10.1007/s11010-013-1675-x. Epub 2013 May 10.

PMID:
23660953
13.

Amyloid-β protein modulates insulin signaling in presynaptic terminals.

Heras-Sandoval D, Ferrera P, Arias C.

Neurochem Res. 2012 Sep;37(9):1879-85. doi: 10.1007/s11064-012-0800-7. Epub 2012 May 26.

PMID:
22638775
14.

Proteostasis impairment: at the intersection between Alzheimer's disease and diabetes.

Medinas DB, Hetz C.

Cell Metab. 2013 Dec 3;18(6):771-2. doi: 10.1016/j.cmet.2013.11.009.

15.

Toward Alzheimer's prevention.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2007 Feb;18(12):1-3. No abstract available.

PMID:
17340746
16.

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.

Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM.

J Alzheimers Dis. 2005 Dec;8(3):247-68.

PMID:
16340083
17.

Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats.

Baraka A, ElGhotny S.

Eur J Pharmacol. 2010 Sep 1;641(2-3):123-7. doi: 10.1016/j.ejphar.2010.05.030. Epub 2010 Jun 8.

PMID:
20639139
18.

[The role of incretins. Type 2 diabetes with new beginnings].

[No authors listed]

MMW Fortschr Med. 2005 Mar 10;147(10):48-9. German. No abstract available.

PMID:
15803785
19.

Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathology.

Zhao Z, Ho L, Wang J, Qin W, Festa ED, Mobbs C, Hof P, Rocher A, Masur S, Haroutunian V, Pasinetti GM.

FASEB J. 2005 Dec;19(14):2081-2. Epub 2005 Sep 26.

20.

Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.

Okada H, Ouchi Y, Ogawa M, Futatsubashi M, Saito Y, Yoshikawa E, Terada T, Oboshi Y, Tsukada H, Ueki T, Watanabe M, Yamashita T, Magata Y.

Brain. 2013 Oct;136(Pt 10):3004-17. doi: 10.1093/brain/awt195. Epub 2013 Aug 24.

Items per page

Supplemental Content

Write to the Help Desk